When Cytokinetics, Inc. announced the positive results of its Phase III SEQUOIA-HCM study of the cardiac myosin inhibitor aficamten in 282 patients with the rare disease obstructive hypertrophic cardiomyopathy (oHCM) in late December, its investors were quick to forgive Santa’s tardiness and pushed its stock price up by over 82%. By comparison, the NASDAQ Biotech Index (NBI) closed up by under 2% that day. Until the last few days of the year, 2023 had been a year to forget at Cytokinetics with its CEO describing it as “challenging year” after only the first quarter.
Stock Watch: Cytokinetics – From Certain Villain To Possible Hero
But Positive Phase III Study May Not Result In Big Pharma Acquisition
Investors’ euphoria on Cytokinetics’ positive Phase III study may be tempered by its high debt, pass-through royalties, entrenched competition and the FTC in the terms of any transaction.
More from Stock Watch
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
• By
Two pharmaceutical companies reporting bumper sales in the hot areas of diabetes and obesity may have helped a thaw in sector sentiment.
More from Business
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.